Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nanobody Sequencing Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nanobody Sequencing Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical researchers and antibody engineers, discovering and characterizing nanobodies (VHH) is essential for developing next-generation biologics. Nanobody sequencing service addresses this by using high-throughput sequencing and bioinformatics to rapidly obtain complete variable region gene sequences from immune animals (camels, alpacas) or synthetic libraries. The service encompasses RNA extraction, cDNA synthesis, specific PCR amplification, library construction and sequencing, sequence assembly, CDR region identification, germline tracing, and affinity prediction—accurately identifying amino acid and nucleotide sequences of functional nanobodies. As the core first step in nanobody discovery and engineering, sequencing services provide critical foundational data for subsequent expression, humanization, affinity optimization, and drug development.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6099005/nanobody-sequencing-service
Market Size and Growth Fundamentals
The global nanobody sequencing service market was valued at US$ 142 million in 2025 and is projected to reach US$ 199 million by 2032, growing at a CAGR of 5.0% from 2026 to 2032. Growth is driven by expanding nanobody therapeutics pipelines, increasing adoption of nanobodies in diagnostics and imaging, and demand for rapid, accurate VHH sequence identification.
Service Overview and Sequencing Workflow
Nanobody sequencing service follows a structured workflow:
- RNA Extraction: Isolation of total RNA from immune animal lymphocytes (camelid peripheral blood or lymphoid tissue) or library material
- cDNA Synthesis: Reverse transcription of VHH-encoding mRNA
- Specific PCR Amplification: Primers targeting variable regions of heavy-chain-only antibodies (VHH)
- Library Construction and Sequencing: High-throughput sequencing (NGS) or traditional Sanger sequencing
- Bioinformatics Analysis: Sequence assembly, CDR1/CDR2/CDR3 identification, germline gene assignment, affinity prediction
Key output data:
- Complete VHH Variable Region Sequence: Nucleotide and translated amino acid sequence
- CDR3 Identification: The critical antigen-binding loop (highly variable)
- Germline Tracing: Identification of parental V and J genes
- Affinity Prediction: In silico ranking of clones by predicted binding
- Diversity Analysis: Clonal abundance and repertoire diversity statistics
Market Segmentation: Sequencing Types and Applications
The nanobody sequencing service market is segmented by sequencing type into:
- High-throughput Sequencing (NGS) : Largest and fastest-growing segment (approximately 70% of market value). Enables comprehensive immune repertoire analysis; identifies hundreds to thousands of unique VHH sequences per sample. Preferred for discovery projects requiring diversity assessment.
- Traditional Sequencing (Sanger) : Single-clone sequencing for validation and confirmatory applications. Lower throughput; suitable for confirming sequences of lead candidates.
By application, the market spans Antibody Drug Development, Diagnostic Reagent Development, and Other:
- Antibody Drug Development: Largest segment (approximately 65%), including therapeutic nanobody discovery, lead candidate sequencing, and engineering
- Diagnostic Reagent Development: Nanobody-based diagnostic assays, imaging agents, and biosensors
- Other: Research reagents and affinity purification tools
Competitive Landscape: Key Players
The nanobody sequencing service market features specialized antibody discovery CROs and broader biologics service providers:
| Company | Key Strengths |
|---|---|
| Rapid Novor | Protein sequencing specialist; nanobody sequencing from protein samples |
| Sino Biological | Chinese biologics leader; antibody and recombinant protein services |
| Genscript | Gene synthesis and antibody discovery; nanobody services |
| Proteintech | Antibody and protein reagents; custom services |
| Jotbody | Nanobody discovery specialist |
| Mtoz Biolabs, PeotTech, KMD Bioscience, Abace Biology, cusabio | Regional CROs and service providers |
Recent Developments (Last 6 Months)
Several developments have shaped the nanobody sequencing service market:
- Nanobody Therapeutics Pipeline: December 2025–January 2026 saw continued growth in nanobody drug pipelines (over 20 candidates in clinical development, including caplacizumab, ozoralizumab, sonelokimab), driving demand for discovery services.
- CAR-T and Cell Therapy: Nanobodies as CAR-T targeting domains (e.g., anti-BCMA, anti-CD19) increased demand for VHH sequencing for cell therapy applications.
- Diagnostic Applications: Nanobody-based diagnostics for infectious diseases, oncology, and immunoassays expanded beyond drug development.
- AI for Nanobody Discovery: Machine learning algorithms for predicting nanobody-antigen interactions and affinity ranking integrated into sequencing service workflows.
Exclusive Insight: High-Throughput vs. Traditional Sequencing—Discovery vs. Validation
A critical market dynamic is the divergence between high-throughput NGS and traditional Sanger sequencing based on project stage and information requirements.
High-Throughput Sequencing (NGS) (largest and fastest-growing) is characterized by:
- Comprehensive Repertoire: Thousands to millions of sequences per sample
- Diversity Assessment: Clonal abundance, CDR3 length distribution, germline usage
- Applications: Discovery campaigns, immune repertoire analysis, library characterization
- Timeline: 2–4 weeks
- Cost: Lower per-sequence cost for large numbers of clones
Traditional Sequencing (Sanger) (confirmatory segment) is characterized by:
- Single-Clone Resolution: High-quality sequence for individual clones
- Validation: Confirmation of lead candidate sequences post-discovery
- Applications: Lead candidate sequencing, clone verification, small-scale projects
- Timeline: 3–7 days
- Cost: Higher per-sequence cost for small numbers
A 2026 industry analysis indicated that NGS is standard for initial discovery campaigns where diversity assessment is critical. Sanger sequencing remains essential for validation and quality control of lead candidates.
Technical Challenges and Innovation Directions
Key technical considerations in nanobody sequencing service include:
- VHH-Specific Amplification: Avoiding cross-amplification of conventional antibody heavy chains
- CDR3 Diversity: Accurate sequencing of highly diverse and sometimes long CDR3 loops
- Germline Assignment: Correctly assigning V and J germline genes for humanization
- Phasing: Resolving sequences from closely related VHH variants
Innovation focuses on:
- Long-Read Sequencing: PacBio and Oxford Nanopore for full-length VHH phasing
- Single-Cell Sequencing: Direct pairing of VHH sequence with antigen specificity (B cell receptor sequencing)
- Direct Protein Sequencing: Mass spectrometry-based sequencing without nucleic acid amplification
- AI-Assisted Annotation: Machine learning for CDR identification and affinity prediction
Conclusion
The nanobody sequencing service market is positioned for steady growth through 2032, driven by nanobody therapeutics pipelines, diagnostic applications, and cell therapy targeting domains. For service providers, success will depend on VHH-specific amplification accuracy, bioinformatics capabilities, and integration with downstream expression and engineering. As nanobodies gain prominence in drug development and diagnostics, sequencing services will remain the essential first step in nanobody discovery and engineering.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
